MyomoMYO
MYO
About: Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The Company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The Company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).
Employees: 106
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
3,080% more call options, than puts
Call options by funds: $159K | Put options by funds: $5K
300% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 3
50% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 8
21% more funds holding
Funds holding: 34 [Q2] → 41 (+7) [Q3]
6% more capital invested
Capital invested by funds: $37.2M [Q2] → $39.4M (+$2.23M) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
7.65% less ownership
Funds ownership: 40.19% [Q2] → 32.54% (-7.65%) [Q3]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$7.50
25%
upside
Avg. target
$8.50
42%
upside
High target
$9
50%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Craig-Hallum Craig Knickerbocker 50% 1-year accuracy 1 / 2 met price target | 50%upside $9 | Buy Maintained | 13 Dec 2024 |
HC Wainwright & Co. Sean Lee 57% 1-year accuracy 13 / 23 met price target | 25%upside $7.50 | Buy Reiterated | 13 Nov 2024 |
Ascendiant Capital Edward Woo 46% 1-year accuracy 31 / 68 met price target | 50%upside $9 | Buy Maintained | 12 Nov 2024 |
Financial journalist opinion
Positive
MarketBeat
1 month ago
Top 3 Cutting-Edge Micro-Caps Set for 2025 Growth
As 2025 approaches, several promising micro-cap stocks are gaining attention for their potential to disrupt key industries. These companies, though small in market size, are making significant strides with innovative technologies and strategic advancements.
Neutral
Business Wire
1 month ago
Myomo, Inc. Prices $15.0 Million Public Offering of Common Stock
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it has priced an underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $5.00 per share. Myomo expects the gross proceeds from this offering to be approximately $15.0 million, before deducting the underwriting discount.
Neutral
Business Wire
1 month ago
Myomo, Inc. Announces Proposed Public Offering of Common Stock
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. In connection with the offering, Myomo also expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock offered in t.
Neutral
Seeking Alpha
2 months ago
Myomo, Inc. (MYO) Q3 2024 Earnings Call Transcript
Myomo, Inc. (MYO) Q3 2024 Earnings Call Transcript
Negative
Zacks Investment Research
2 months ago
Myomo, Inc. (MYO) Reports Q3 Loss, Tops Revenue Estimates
Myomo, Inc. (MYO) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.06 per share a year ago.
Neutral
Business Wire
2 months ago
Myomo Reports Record Third Quarter Financial and Operating Results
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and nine months ended September 30, 2024. Financial and operating highlights for the third quarter of 2024 include the following (all comparisons are with the third quarter of 2023 unless otherwise indicated): Product a.
Positive
Seeking Alpha
2 months ago
CMS Decision And O&P Network Build Out Make Myomo A Buy
Myomo's business model is now sustainable due to CMS reclassifying MyoPro, leading to lump sum payments and consistent insurance coverage. Medicare Part B coverage has significantly improved Myomo's operating margin and accelerated its product sales growth. The development of an Orthopedic and Prosthetic clinic network will lower customer acquisition costs and create recurring sales, enhancing long-term growth & margins.
Neutral
Business Wire
2 months ago
Myomo Announces First Private Payer Contracts for MyoPro In-network Coverage
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces it has entered into the first contracts that will allow MyoPro to be provided to patients covered by private insurance on an in-network basis. These new contracts are with Blue Cross Blue Shield of Massachusetts, a leading commercial and Medicare Advantage.
Neutral
Business Wire
2 months ago
Myomo to Report Third Quarter Financial Results on November 6, 2024
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the third quarter ended September 30, 2024 on November 6, 2024. The Company will host a conference call the same day, Wednesday November 6, 2024 at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairm.
Neutral
Business Wire
3 months ago
Myomo to Participate in the 2024 Maxim Healthcare Virtual Summit
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, president and chief executive officer, and David Henry, chief financial officer, will participate in a “Fireside Chat” at the 2024 Maxim Healthcare Virtual Summit. The virtual summit is being presented by Maxim Group LLC, from Octob.
Charts implemented using Lightweight Charts™